HC Wainwright Gives Zevra Buy Rating and Sells FDA Credit

Summary

HC Wainwright has given Zevra a buy rating with a target price of $26, highlighting the strong US launch and long-term growth potential of Miplyffa. Zevra sold its FDA voucher for $150 million. Miplyffa received NPC approval in September 2024 and may enter the EU market in 2026.Benzinga

Impact Analysis

The event is classified as a company-level event. The buy rating from HC Wainwright coupled with a target price implies positive expectations for Zevra’s stock, potentially boosting investor confidence. The sale of the FDA voucher for $150 million strengthens Zevra’s cash position, enabling further investment or debt reduction. Miplyffa’s approval and potential EU market entry signal future revenue streams, enhancing long-term growth prospects. Direct impacts include potential stock price appreciation and increased investment interest. Secondary effects could involve competitive positioning in the pharmaceutical industry, given Miplyffa’s expanded market presence. Investment opportunities may arise in Zevra’s stock, particularly if the market underestimates the value of these developments.Benzinga